Bookmark and Share
BioAssay: AID 629235

Displacement of [3H]estradiol from human recombinant ERalpha assessed as relative binding affinity after 1 hr by liquid scintillation counting relative to estradiol

17beta-Hydroxysteroid dehydrogenase type 2 (17beta-HSD2) catalyzes the oxidation of the highly potent steroids: the estrogen estradiol (E2) and the androgen testosterone (T) to the less active estrone and androstenedione, respectively. Inhibition of this enzyme may help maintain the local E2 level in bone tissue when the circulating E2 level drops and is therefore a novel and promising approach more ..
_
   
 Tested Compounds
 Tested Compounds
All(34)
 
 
Unspecified(34)
 
 
 Tested Substances
 Tested Substances
All(34)
 
 
Unspecified(34)
 
 
 Related BioAssays
 Related BioAssays
AID: 629235
Data Source: ChEMBL (786683)
Depositor Category: Literature, Extracted
BioAssay Version:
Deposit Date: 2012-09-09
Modify Date: 2014-08-23

Data Table ( Complete ):           View All Data
Target
Sequence: RecName: Full=Estrogen receptor; Short=ER; AltName: Full=ER-alpha; AltName: Full=Estradiol receptor; AltName: Full=Nuclear receptor subfamily 3 group A member 1
Description ..   
Protein Family: Ligand binding domain of Estrogen receptor, which are activated by the hormone 17beta-estradiol (estrogen)
Comment ..   

Gene:ESR1     Related Protein 3D Structures     More BioActivity Data..
Tested Compounds:
Description:
Title: Triazole ring-opening leads to the discovery of potent nonsteroidal 17beta-hydroxysteroid dehydrogenase type 2 inhibitors.

Abstract: 17beta-Hydroxysteroid dehydrogenase type 2 (17beta-HSD2) catalyzes the oxidation of the highly potent steroids: the estrogen estradiol (E2) and the androgen testosterone (T) to the less active estrone and androstenedione, respectively. Inhibition of this enzyme may help maintain the local E2 level in bone tissue when the circulating E2 level drops and is therefore a novel and promising approach for the treatment of osteoporosis. In this work, a series of new nonsteroidal and achiral 17beta-HSD2 inhibitors, namely N-benzyl-diphenyl-3(or 4)-carboxamide and N-benzyl-5-phenyl-thiophene-2-carboxamide was designed and the compounds were synthesized in a two to three steps reaction. A small library was built applying parallel synthesis. Highly potent 17beta-HSD2 inhibitors could be identified in the thiophene-2-carboxamide class with IC(50) in the low nanomolar range. These compounds also showed a good selectivity profile toward 17beta-HSD1 and toward the estrogen receptors alpha and beta. The most interesting 17beta-HSD2 inhibitor identified in this study is the 5-(2-fluoro-3-methoxyphenyl)-N-(3-hydroxybenzyl)-N-methylthiophene-2-carboxamide 6w displaying an IC(50) of 61 nM and a selectivity factor of 73 toward 17beta-HSD1.
(PMID: 22037253)
Categorized Comment - additional comments and annotations
From BioAssay Depositor:
Assay Type: Binding
Target Type: Target is a single protein chain
Assay Data Source: Scientific Literature
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1RBA activity commentRBA activity commentString
2RBA standard flagRBA standard flagInteger
3RBA qualifierRBA qualifierString
4RBA published valueRBA published valueFloat%
5RBA standard valueRBA standard valueFloat%

Data Table (Concise)
Data Table ( Complete ):     View All Data
PageFrom: